[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633882":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":58,"collaborators":62,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":25,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":93,"whyStopped":25,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Psychiatric University Hospital, Zurich","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Sequence AB","EXPERIMENTAL","Participants receive fampridine (A) in one experimental session and placebo (B) in the other, in the order A then B.",[13,14],"Drug: 4-aminopyridine (4-AP)","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Sequence BA","Participants receive placebo (B) in one experimental session and fampridine (A) in the other, in the order B then A.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","4-aminopyridine (4-AP)","Two doses of fampridine administered during one of the two experimental test sessions.",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","Matching placebo administered during one of the two experimental test sessions.",[9,16],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Prof. Dr. rer. nat. Boris B. Quednow, Dr. rer. nat.","CONTACT","+41 58 384 27 77","quednow@bli.uzh.ch",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Laura V Schurek, M. Sc.","+41 58 384 26 16","studie-potchicud@bli.uzh.ch",[41],{"facility":42,"status":25,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"University Hospital of Psychiatry Zurich","Zurich","Canton of Zurich","8008","Switzerland","CH",{"type":49,"coordinates":50},"Point",[51,52],8.55,47.36667,{"lat":52,"lon":51},[55,56],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"name":57,"role":33,"phone":38,"phoneExt":25,"email":39},"Laura V. Schurek, M. Sc.",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Boris Quednow","Full Professor for Experimental Pharmacopsychology and Psychological Addiction Research",[63],{"name":64,"class":6},"University of Zurich","100633882","the-role-of-potassium-channels-in-working-memory-impairments-of-chronic-cocaine-users-100633882",false,"NCT07532460","The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users","Randomised, Double-Blind, Placebo-Controlled, Crossover Study Investigating the Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users","POTCHICUD","Inclusion Criteria:\n\n* Current diagnosis of mild, moderate, or severe CoUD according to DSM-5\n* Minimum cocaine use of 1g\u002Fmonth in the last three months\n* Cocaine as the primary drug of consumption\n* Willingness to abstain from cocaine use at least 72 hours before prior to each study visit\n* Ability to read, understand and provide written informed consent\n* To be sufficiently fluent in German\n* Age between 20 and 50 years\n* Body mass index (BMI) between 19 and 30 kg\u002Fm2\n* If applicable: luteal phase of the menstrual cycle\n* For individuals with childbearing potential: use of contraceptive measures\n\nExclusion Criteria:\n\n* Presence or history of severe neurological disorders or head injuries\n* Current diagnosis of an acute or chronic infectious disease\n* If applicable: pregnancy and breastfeeding\n* Lifetime history of any epileptic seizures\n* Lifetime diagnosis of a cardiovascular disease, specifically arrhythmia and long QT syndrome\n* Clinically significant laboratory or ECG abnormality that could be a safety issue in the study\n* Lifetime diagnosis of liver or kidney disease including moderate or severe renal impairment (creatinine clearance \\\u003C 50 ml\u002Fmin)\n* Known hypersensitivity or allergy to 4-aminopyridine\n* Use of potassium channel blockers within the last 3 months\n* Use of psychotropic medication within the last 7 days\n* Use of inhibitors of the organic cation transporter 2 (OCT2), such as cimetidine\n* Lifetime diagnosis of schizophrenia, bipolar disorder, obsessive-compulsive disorder, or autism spectrum disorder according to DSM-5\n* Diagnosis of a current episode of depression\n* Current diagnosis of a moderate or severe substance use disorder other than CoUD according than DSM-5\n* Daily cannabis consumption in the past three months\n* (E-Cigarette) Fagerström Test of Nicotine Dependence Score \\> 5 (strong nicotine dependence)\n* Inability to follow the procedures of the study, e.g., due to language problems\n* Being related to or in any form dependent on the investigator\n* Prior participation (less than two years ago) in a study investigating working memory using the n-back task, the SWM, PAL, RVP, or LNST\n* Participation in another study with investigational drugs within the 30 days preceding and during the present study","ALL","20 Years","50 Years",{"count":77,"type":78},40,"ESTIMATED","INTERVENTIONAL",[81],"NA","The study aims to address the neurobiological basis of cognitive impairments in chronic cocaine users by investigating the potential impact of an acute potassium channel blockade on working memory performance and other cognitive functions.",[84,85],"Cocaine Use Disorder (CUD)","Cognitive Impairments",[87,88,89,90,91,92],"cognitive impairments","cocaine use disorder","potassium channels","working memory","4-aminopyridine","fampridine","NOT_YET_RECRUITING","2026-04-15",{"date":96,"type":97},"2026-04-20","ACTUAL",{"date":99,"type":78},"2026-04",{"date":101,"type":78},"2027-08",{"name":60,"class":6},1]